Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Time Limited Exposure to a ROR1 Targeting Bispecific T Cell Engager (NVG-111) Leads to Durable Responses in Subjects with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

William Townsend, Sarah Leong, Mittal Shah, Toby Batten, David Tucker, Bryson Pottinger, Shankaranarayana Paneesha, Dima El-Sharkawi, Toby A. Eyre, Ho Pui Jeff Lam, Jiexin Zheng, Sarah Cook, David Granger, David Ahern, Kieran O'Donovan, Amit C. Nathwani, Parag Jasani

Blood (2023) 142 (Supplement 1): 329.

https://doi.org/10.1182/blood-2023-188607

Published: 2023

Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Blood (2023) 142 (Supplement 1): 631.

https://doi.org/10.1182/blood-2023-178298

Published: 2023

Journal Articles

R-GEM-Lenalidomide Versus R-GEM-P As Second-Line Treatment of Diffuse Large B-Cell Lymphoma: Results from the UK NCRI Phase II Randomized Legend Trial

Andrea Kuhnl, MD, Clare Peckitt, Bijal Patel, Kirit M Ardeshna, MD, Marian P Macheta, John Radford, MD, Rod Johnson, Shankaranarayana Paneesha, Sarah Barton, Ian Chau, MD, Martin F Kaiser, MD, Ruwaida Begum, Nicola Valeri, Andrew Wotherspoon, Yong Du, Imene Zerizer, David Cunningham, MD FRCP

Blood (2017) 130 (Supplement 1): 2829.

https://doi.org/10.1182/blood.V130.Suppl_1.2829.2829

Published: 2017

Journal Articles

Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product "MSC-Ffm" Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients

Blood (2017) 130 (Supplement 1): 514.

https://doi.org/10.1182/blood.V130.Suppl_1.514.514

Published: 2017

Journal Articles

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Hatem Ali, MBBS, Baharani Jyoti, MBBS, FRCP, Shankaranarayana Paneesha, MD, Richard Lovell, Alex George Kanellopoulos, MD, Evgenia Xenou, MD, Iman Qureshi, MBBS, MRCP, Lorna Cain, Maria Kaparou, David John Sutton, MBBChir, MRCP, BSc, Rebecca Pryor, MB, MRCP, Emmanouil Nikolousis, PhDMBBS,FRCPath,MBA, Bhuvan Kishore, MBBS, MRCP, FRCPath

Blood (2016) 128 (22): 5822.

https://doi.org/10.1182/blood.V128.22.5822.5822

Published: 2016

Journal Articles

Single Centre Experience of Managing Patients with Double Hit Lymphoma

Shankaranarayana Paneesha, MD FRCP, FRCPath, Iman Qureshi, MBBS, MRCP, Malahat Saeed, MBBS MRCP, Richard Lovell, Emmanouil Nikolousis, PhDMBBS,FRCPath,MBA, Bhuvan Kishore, MBBS, MRCP, FRCPath, Kathy Holder, Maria Kaparou

Blood (2016) 128 (22): 5868.

https://doi.org/10.1182/blood.V128.22.5868.5868

Published: 2016

Journal Articles

Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial

Elizabeth H Phillips, Amy A Kirkwood, Anthony Lawrie, Simon Rule, Russell Patmore, MRCP FRCPath, Ruth Pettengell, Cathy H Burton, Kirit M Ardeshna, Silvia Montoto, MD, Shankaranarayana Paneesha, Paul Smith, Katharina Wanek, Laura Clifton-Hadley, PhD BSc, David C. Linch, MD MRCP, MB BCh, BA, Andrew McMillan, PhD

Blood (2016) 128 (22): 1855.

https://doi.org/10.1182/blood.V128.22.1855.1855

Published: 2016

Journal Articles

12-Month Full Donor Chimerism Is Associated with Low-Grade Acute Graft Versus Host Disease (aGVHD) and Predicts Superior Outcomes in Reduced Intensity (RIC) Alemtuzumab-Based Transplants for MDS and AML

Alex George Kanellopoulos, MD, Shankaranarayana Paneesha, MD, Evgenia Xenou, MD, Iman Qureshi, MBBS, MRCP, Dewi Tomos Eden, MRCP,MB,FRCPath, David John Sutton, MBBChir, MRCP, BSc, Rebecca Pryor, MB, MRCP, Lorna Cain, Carolina Arbuthnot, Richard Lovell, Anton Borg, MDFRCP,FRCPath, Katie Randall, MB, FRCPath, Kathy Holder, Julie Suhr, Lynda Baker, Lynn Ryan, Maria Kaparou, Bhuvan Kishore, MBBS, MRCP, FRCPath, Emmanouil Nikolousis, PhD MBBS, FRCPath, MBA

Blood (2016) 128 (22): 5764.

https://doi.org/10.1182/blood.V128.22.5764.5764

Published: 2016

Journal Articles

Colony Stimulating Factors (Pegfilgrastim or Lenograstim) Use in Patients with Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is Associated with Early Neutrophil Engraftment and Shorter Inpatient Stay with No Impact on Progression Free Survival (PFS) or Overall Survival (OS)

Georgina Mayer, Bhuvan Kishore, MBBS, FRCPATH, MRCP, Richard Lovell, Emmanouil Nikolousis, PhD, Shankaranarayana Paneesha, MD FRCP, FRCPath

Blood (2015) 126 (23): 5450.

https://doi.org/10.1182/blood.V126.23.5450.5450

Published: 2015

Journal Articles

A Retrospective Single Center Comparison of Cyclophosphamide Plus G-CSF Versus G-CSF Alone for Peripheral Blood Stem Cell (PBSC) Mobilisation Following First Line Therapy in Patients with Multiple Myeloma

Richard S Whitmill, MBCHB FRCPath, David J Lewis, David John Sutton, MBBChir, MRCP, BSc, Jahanzeb Khawaja, MB CHB MRCP, Georgina Mayer, MB CHB MRCP, Shankaranarayana Paneesha, MD, Emmanouil Nikolousis, PhD, Bhuvan Kishore, MBBS, FRCPATH, MRCP

Blood (2015) 126 (23): 1898.

https://doi.org/10.1182/blood.V126.23.1898.1898

Published: 2015

Journal Articles

Autologous Stem Cell Transplant Has a Role In Consolidating Chemotherapy Given At First Disease Progression In Multiple Myeloma Treated Exclusively With Novel Agents

Blood (2013) 122 (21): 5514.

https://doi.org/10.1182/blood.V122.21.5514.5514

Published: 2013

Journal Articles

Is Daily Lenograstim From Day +7 Of Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is As Effective As Pegfilgrastim In Patients With Myeloma?

Ben Bailiff, Neil Phillips, Vidhya Murthy, Lynn Bratby, Kathy Holder, Bhuvan Kishore, E Nikolousis, R Lovell, Guy Pratt, Joanne Ewing, Shankaranarayana Paneesha

Blood (2013) 122 (21): 5538.

https://doi.org/10.1182/blood.V122.21.5538.5538

Published: 2013

Journal Articles

Full Donor T Cell Chimerism Predicts Transplant Outcomes In High Risk AML But Not In Intermediate Risk AML After a T-Deplete Alemtuzumab Conditioned Transplant

Amy Gudger, Vidhya Murthy, Duncan J Murray, MA MRCP, Ben Bailiff, Maria Mushkbar, Jonathan ray Lancashire, MBBS, MRCP, Phillip Nicolson, Kathy Holder, Lynda Baker, Lynn Bratby, Bhuvan Kishore, Richard Lovell, Shankaranarayana Paneesha, Nikolousis Emmanouil, MRCP, FRCPath, Ph.D

Blood (2013) 122 (21): 5545.

https://doi.org/10.1182/blood.V122.21.5545.5545

Published: 2013

Journal Articles

Pre-Transplantation Assessment Of Mortality (PAM) Score Is a Poor Predictor For Survival In The Highest Risk Group When Used In T Cell Depleted Myeloablative Allogeneic Transplants

Bhuvan Kishore, Daniel Wiseman, MBChB, MRCP, Emmanouil Nikolousis, Richard Lovell, Donald Milligan, MD, Kathy Holder, Lynn Bratby, Vidhya Murthy, Shankaranarayana Paneesha

Blood (2013) 122 (21): 5553.

https://doi.org/10.1182/blood.V122.21.5553.5553

Published: 2013

Journal Articles

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Andrew McMillan, FRCP, FRCPath, PhD, Kirit M Ardeshna, FRCPath, Jo Gambell, Andrew Jack, PhD, Amy Kirkwood, Anthony Laurie, Silvia Montoto, MD, Shankaranarayana Paneesha, MD, Simon Rule, MD, Russell Patmore, MD, Ruth Pettengell, Humra Shah, Paul Smith, David Linch, FMedSci

Blood (2013) 122 (21): 4348.

https://doi.org/10.1182/blood.V122.21.4348.4348

Published: 2013

Journal Articles

Utility of Blood Cultures in Febrile Patients in a BCSH Level 4 Centre

Sophie Lee, Kesavan Kandiah, Kate Holyhead, Sandar Aung, Neil Smith, Emmanouil Nikolousis, Shankaranarayana Paneesha

Blood (2011) 118 (21): 4779.

https://doi.org/10.1182/blood.V118.21.4779.4779

Published: 2011

Journal Articles

Pegfilgrastim Use in Patients with Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is Associated with Early Neutrophil Engraftment and Shorter Inpatient Stay.

Neil Phillips, Anand Lokare, Kathy Holder, Sridhar Chaganti, Richard Lovell, Shankaranarayana Paneesha, Donald Milligan

Blood (2009) 114 (22): 2275.

https://doi.org/10.1182/blood.V114.22.2275.2275

Published: 2009

Journal Articles

Assessment of Clinical Risk Factors for Symptomatic Venous Thromboembolism in Common Cancers: A VERITY Registry Study

Shankaranarayana Paneesha, MD, Aidan McManus, PhD, Roopen Arya, MBBS, PhD, Nicholas Scriven, MB, Tim Nokes, MD, Timothy Farren, BSc, Sue Bacon, SRN, Anthea Nieland, SRN, Denise O’Shaughnessy, MD, PhD, Peter Rose, MD

Blood (2008) 112 (11): 3826.

https://doi.org/10.1182/blood.V112.11.3826.3826

Published: 2008

Journal Articles

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Emmanouil Nikolousis, Charles F. Craddock, BM, MRCP, MRCPath, Shankaranarayana Paneesha, MD, Sudhir Tauro, Prem Mahendra, II, Mark Cook, Fiona Clark, Richard Lovell, Sridhar Chaganti, Donald Milligan, MD, MBChB, Dominique Mcmullan, Mike Griffiths, Stephen P Robinson, MD

Blood (2008) 112 (11): 4409.

https://doi.org/10.1182/blood.V112.11.4409.4409

Published: 2008

Journal Articles

Transplant Outcome Is Not Affected by Body Mass Index (BMI) in Patients with Haematological Malignancies.

Emmanouil Nikolousis, Shankaranarayana Paneesha, MD MRCP MRCPath, Kathy Holder, Lynn Bratby, Srinivas Pillai, Richard Lovell, Don Milligan, MD FRCP FRCPath

Blood (2007) 110 (11): 1991.

https://doi.org/10.1182/blood.V110.11.1991.1991

Published: 2007

NARROW

Time Limited Exposure to a ROR1 Targeting Bispecific T Cell Engager (NVG-111) Leads to Durable Responses in Subjects with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

R-GEM-Lenalidomide Versus R-GEM-P As Second-Line Treatment of Diffuse Large B-Cell Lymphoma: Results from the UK NCRI Phase II Randomized Legend Trial

Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product "MSC-Ffm" Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Single Centre Experience of Managing Patients with Double Hit Lymphoma

Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial

12-Month Full Donor Chimerism Is Associated with Low-Grade Acute Graft Versus Host Disease (aGVHD) and Predicts Superior Outcomes in Reduced Intensity (RIC) Alemtuzumab-Based Transplants for MDS and AML

A Retrospective Single Center Comparison of Cyclophosphamide Plus G-CSF Versus G-CSF Alone for Peripheral Blood Stem Cell (PBSC) Mobilisation Following First Line Therapy in Patients with Multiple Myeloma

Autologous Stem Cell Transplant Has a Role In Consolidating Chemotherapy Given At First Disease Progression In Multiple Myeloma Treated Exclusively With Novel Agents

Is Daily Lenograstim From Day +7 Of Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is As Effective As Pegfilgrastim In Patients With Myeloma?

Full Donor T Cell Chimerism Predicts Transplant Outcomes In High Risk AML But Not In Intermediate Risk AML After a T-Deplete Alemtuzumab Conditioned Transplant

Pre-Transplantation Assessment Of Mortality (PAM) Score Is a Poor Predictor For Survival In The Highest Risk Group When Used In T Cell Depleted Myeloablative Allogeneic Transplants

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Utility of Blood Cultures in Febrile Patients in a BCSH Level 4 Centre

Pegfilgrastim Use in Patients with Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is Associated with Early Neutrophil Engraftment and Shorter Inpatient Stay.

Assessment of Clinical Risk Factors for Symptomatic Venous Thromboembolism in Common Cancers: A VERITY Registry Study

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Transplant Outcome Is Not Affected by Body Mass Index (BMI) in Patients with Haematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only